Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.

Clinical lung cancer - 1 Sept 2015

Liu Jia-Tao, Li Wen-Cheng, Gao Shuang, Wang Fang, Li Xiao-Qiu, Yu Han-Qing, Fan Lu-Lu, Wei Wei, Wang Hua, Sun Guo-Ping

Abstract excerpt

BACKGROUND: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). In the present study, the role of autophagy in the combination of gefitinib and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Autophagy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chloroquine

Share to Cisplatin

Share to Drug Synergism

Share to Gefitinib

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 25979647
DOI: 10.1016/j.cllc.2015.03.006

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.PMID 25979647Read ↗

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy.Semantic proximity Read ↗

Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cellsSemantic proximity Read ↗

Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancerSemantic proximity Read ↗

Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.Semantic proximity Read ↗

Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.Semantic proximity Read ↗

Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.Semantic proximity Read ↗

Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?Semantic proximity Read ↗

Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.Semantic proximity Read ↗

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.Semantic proximity Read ↗

Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivoSemantic proximity Read ↗

Combined treatment with N-acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line.Semantic proximity Read ↗

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.